Fidaxomicin monotherapy versus standard therapy combined with bezlotoxumab for treating patients with Clostridioides difficile infection at high risk of recurrence: a matched cohort study
| Autor: | Rosa Escudero-Sanchez, Alfonso Muriel García, Sergio García Fernández, Angela Valencia Alijo, Mariona Tasias Pitarch, Esperanza Merino De Lucas, Angela Gutierrez Rojas, Antonio Ramos Martínez, Miguel Salavert Lletí, Livia Giner, María Ruíz Ruigomez, Lorena García Basas, Jorge Fernández Fradejas, María Olmedo Sampedrio, Angela Cano Yuste, Beatriz Díaz Pollán, María Jesús Rodríguez Hernández, Oriol Martín Segarra, Carmen Sáez Bejar, Carlos Armiñanzas Castillo, Belén Gutiérrez, Dolors Rodríguez-Pardo, Julián De La Torre Cisneros, Francisco López Medrano, Javier Cobo Reinoso |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Pharmacology
Microbiology (medical) DISEASES SOCIETY OUTCOMES IMPACT Antibodies Monoclonal VANCOMYCIN GUIDELINES Anti-Bacterial Agents Cohort Studies HEALTH-CARE EPIDEMIOLOGY AMERICA IDSA Infectious Diseases Treatment Outcome CLINICAL-PRACTICE Recurrence Vancomycin MANAGEMENT Clostridium Infections UPDATE Humans Pharmacology (medical) Broadly Neutralizing Antibodies Fidaxomicin Retrospective Studies |
| Zdroj: | JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante instname r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe |
| ISSN: | 1460-2091 0305-7453 |
| Popis: | Background Both fidaxomicin and bezlotoxumab (used in combination with an antibiotic against Clostridioides difficile) achieve reductions in recurrence rates of C. difficile infection (CDI). However, the two strategies have never been compared. Methods Data from two retrospective cohorts of ‘real-life’ use of fidaxomicin and bezlotoxumab in combination with a standard anti-C. difficile antibiotic were used to compare the rates of recurrence of both strategies. Since the two cohorts were not identical, we used a propensity score analysis. Results Three hundred and two patients were included: 244 in the fidaxomicin cohort and 78 in the bezlotoxumab cohort. A history of renal failure or immunosuppression was more frequent in patients receiving bezlotoxumab (39.7% and 66.7% versus 26.6% and 38.9%; P = 0.03 and P Conclusions We observed that fidaxomicin and bezlotoxumab are prescribed in similar clinical scenarios, although those treated with bezlotoxumab have greater comorbidity. The proportion of recurrences was numerically lower in those treated with bezlotoxumab, although the propensity analysis did not find significant differences between the two drugs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|